GEOFFREY NICHOL
CIK 1214505 · Executive Vice President, R&D · last filed 2026-01-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
4
Total Filings
25
Lifetime Open-Market Net
$0
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TPST | Director | — | $1.26 | — | $0 | 6 | 2026-01-28 |
| Tempest Therapeutics, Inc. (MLND) Delisted | Director | — | $15.90 | — | $0 | 2 | 2020-06-23 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Executive Vice President, R&D | 159,676 | $0.18 | $28.4K | $0 | 7 | 2015-12-15 |
| MEDX | Senior Vice President | 0 | $34.49 | $0 | $0 | 9 | 2009-09-01 |
Recent Filings · Page 3 of 3
25 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2009-02-26 | MEDX | Exer (M) | +5,926 | $0 | EDGAR |
| 2008-03-04 | MEDX | Grant (A) | — | $0 | EDGAR |
| 2007-06-01 | MEDX | Grant (A) | — | $0 | EDGAR |
| 2007-05-18 | MEDX | Grant (A) | — | $0 | EDGAR |
| 2007-02-27 | MEDX | Grant (A) | — | $0 | EDGAR |
Showing 21–25 of 25
Prev
Page 3 of 3
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.